Pharma Capital
EPIC: IXI
Market: AIM
52-week High/Low: 44.00p / 22.00p
Sector: Pharma & Biotech
Market Cap: 8.24M
Phone: +44 (0)20 7691 1122
Address: 2 Royal College Street, London NW1 0NH.
Website: www.ixico.com

Established in 2004 and based in London, UK, at IXICO we put patients at the heart of what we do.

Our innovative technologies help those involved in researching and treating serious brain diseases to make rapid decisions and improve patient outcomes. While our clinical focus is predominantly dementia, we also support clinical studies for other disease areas in the field of neuro-degeneration and beyond.

IXICO Plc

www.ixico.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in IXICO Plc

IXICO Plc Snapshot

At IXICO we work with many of the leading pharmaceutical companies providing clinical trial services and technology to evaluate imaging endpoints as part of their drug development pipelines. We have a dedicated team of project managers, site managers and image analysts working across all phases in disease ranging from Alzheimer's Disease to Prostate Cancer to Liver Disease.

How is our technology used?

Our pioneering medical image management and analysis products are used by the global pharmaceutical industry to select patients for clinical trials and to assess the safety and efficacy of drugs in development.

Our proprietary technologies –  TrialWire™ and TrialTracker™ – have been used in the collection of patient data from more than 400 hospital sites worldwide in several of the largest clinical trials of Alzheimer’s disease treatments.

 

How are we developing our products?

The end-to-end imaging services we offer are intended to support an increasingly personalised approach to medicine and treatment. As such, we are translating the proprietary technology which has been widely used in clinical trials into decision-support tools for the diagnosis of dementia.

These products, including our new medical device, Assessa®, will assist healthcare professionals to provide earlier, differential and accurate diagnosis that can match patients to the most appropriate treatment.

When positive, this should enable patients to access the treatment and support they need to extend their independent life. When negative, it can reassure them that dementia is not the cause of their symptoms.

 

Clinical Trials

Since 2004 IXICO have been providing end-to-end imaging services to the pharmaceutical industry, biotech companies, academia and medical charities.

The exceptional products and services we develop are used to help select patients for enrolment in clinical trials and assess drug safety and efficacy.

All IXICO's clinical trial work is covered by our Quality Management System that is ISO9001:2008 certified and has been externally audited by several top pharma companies.

For more information, please click here

 

Digital Health

IXICO brings innovative digital technologies and services to those involved in researching and treating brain diseases.

Digital Healthcare Products

IXICO has a portfolio of digital healthcare products that personalize the way treatments are given; identifying the right patients to receive a treatment to optimise efficacy, improving safety by detecting potential side effects, and informing clinical decisions by collecting, analysing longitudinal data.​​

For more information, please click here

 

Disease diagnostics

As a world-leading digital healthcare company we produce innovative medical technologies which enable faster and more accurate diagnosis of neurological diseases such as dementia.

For more information, please click here

 

 

 

 

 

 

 

Charles Spicer
Non-Executive Chairman

Charles joined the Board of IXICO in July 2013 having previously been an adviser on corporate strategy to the Board since 2011. He is an experienced Director of, and adviser to, public and private companies primarily in the medtech and life science sectors. He is currently Non-Executive Chairman of Realm Therapeutics plc (formerly PuriCore plc), Creo Medical Group plc and 11 Health Technologies Limited and chairs the UK Department of Health’s Invention for Innovation Funding Panel. He has also served as Non-Executive Director of Stanmore Implants and Aircraft Medical. He was previously Chief Executive of MDY Healthcare plc, a strategic healthcare investor and prior to that, Head of Healthcare Corporate Finance at both Numis Securities and Nomura International. Charles has an MA in History from Cambridge University.

 

 

 

 

 

 

 

 

Derek Hill

Executive Director

Derek is a founder and former CEO of IXICO. He was responsible for setting and delivering the business strategy which has included leading the company to profitability in 2012 and the subsequent admission to AIM in October 2013. Derek has worked in medical imaging science for over 25 years and has authored more than 80 journal papers in this field. He is a member of the MRI Core of the Alzheimers disease Neuroimaging Initiative ADNI in the US, has served on the scientific advisory board for several pharmaceutical companies and is involved in the Critical Path Institute’s Coalition Against Major Diseases CAMD biomarker qualification initiatives. Derek has a PhD in medical image analysis at the Medical School of Guy’s & St Thomas’ Hospitals, University of London, an MSc in Medical Physics at the University of Surrey and a BSc degree in Physics from Imperial College. He undertook business training at London Business School as part of the CSEL programme.

 

 

 

 

 

 

 

 

Tim Sharpington

Non-Executive Director and Senior Independent Director

Tim has more than 25 years’ experience in the life sciences sector with various pharmaceutical, biotechnology and pharmaceutical service companies in Europe and the US. He has broad experience in drug development, product licensing, mergers, acquisitions and fundraisings. Previous positions include Chief Executive Officer at Phytopharm PLC and SerentisLimited , and Executive Vice President at Vectura PLC. Tim led product development at Arakis Ltd. and US-based Sequus Inc. following a period of time at Pfizer. His CRO experience was gained at ICON, one the world’s largest CROs, where he led European operations. Tim was also a Non-Executive Director at Clinical Force Limited, a clinical trial software company, until its successful trade sale in 2011. Tim chairs the Remuneration Committee.

 

 

 

 

 

 

 

 

Giulio Cerroni

Chief Executive Officer

Giulio joined IXICO as Chief Executive Office in February 2017.  He has over 30 years of experience in the life science and diagnostic sectors and has led business operations ranging from £4M to £125M of revenues. He was previously  Managing Director of the Genomics division of the LGC group, the private equity owned international life science measurement and testing company. In addition to trebling revenues in under four years and completing three acquisitions in eighteen months, Giulio was a member of the executive leadership team responsible for the successful sale of LGC group to the leading private equity firm, KKR. Guilio also held a variety of leadership positions across both the Life Science and Anatomical Pathology Divisions at ThermoFisher Scientific. These included Managing Director, Vice President Commercial Operations EMEA and APAC, with his final post being the Global Vice President and General Manager of the 1,200 employee Anatomical Pathology organisation. His first eighteen years were spent in business development and divisional leadership roles with Dupont and Anachem. Giulio holds a BSc from Cardiff University and an MBA (distinction) from Warwick University.

 

 

 

 

 

 

 

 

 

Susan Lowther

Chief Financial Officer and Company Secretary

Susan joined IXICO as Chief Financial Officer in October 2014. She was previously Group Chief Financial Officer and a Director of Novacyt SA, a European diagnostic company listed on the French Alternext exchange. Prior to that, she was Chief Financial Officer and a Director of Lab21 Group Limited which was acquired by Novacyt in June 2014. Susan also held executive positions at BioWisdom Limited where she was Chief Financial Officer until its acquisition by Instem plc and Finance Director at RiboTargets Limited until its acquisition by Vernalis plc. She has held senior financial management roles at other life science companies including Lonza Biologics, Celltech Group and Monsanto, gaining significant experience in growing businesses and corporate transactions.

 

 

 

 

 

 

 

 

Mark Warne

Non-Executive Director

Mark became a Non-Executive Director of IXICO in September 2016.  He is currently Head of IP Group’s Healthcare division which at the end of December 2015 had shareholdings in 31 companies valued at over £275 million. Mark also represents IP Group on the boards of a number of its portfolio companies, both quoted and private; notably hVIVO plc, Genomics plc, Cronin Group plc and Crysalin Limited. Mark has been at IP Group since 2008 and has extensive experience in building world-changing healthcare businesses as well as in managing transactions including portfolio company IPOs, financings and M&A. He joined IP Group from pre-clinical drug discovery CRO, Exelgen, where he was managing director. Mark spent 8 years at Exelgen (formerly known as Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry.

John Bradshaw

Non-Executive Director

John is a chartered accountant with more than 15 years’ experience as a Chief Financial Officer with venture capital backed and listed companies. He is a partner in Bradshaw Daniel, which provides Chief Financial Officer services to small and medium sized companies throughout the UK and Europe. He is the Chief Financial Officer of Syncona Partners LLP, an independent subsidiary of the Wellcome Trust founded in 2012 to invest in healthcare. He was previously Chief Financial Officer of Gyrus Group PLC, which he joined prior to listing it on the London Stock Exchange, following 11 years at Arthur Andersen in Cambridge and Turin where he qualified as a chartered accountant. John has a law degree from the University of Liverpool. John chairs the Audit Committee.

 

For information on the Key Management team, please click here

Major Shareholders

Shareholders holding more than 3% of the share capital of IXICO plc are:

Name Number of Shares Held Percentage %
Invesco Asset Management 6,205,222 22.93
I P Group 5,704,585 21.08
Touchstone Innovations Group plc 3,619,661 13.37
Hardsteel Limited 847,148 3.13

 

 

 

 

 

 

 

Content updated: 26 January 2017.

UK

IXICO PLC.
4th Floor
Griffin Court
15 Long Lane
London
EC1A 9PN

 

USA

IXICO Technologies Inc.
225 Cedar Hill Street
Suite 200
Marlborough, MA 01752
USA

 

Nominated Advisor and Broker

Shore Capital

Bond Street House, 14 Clifford Street, London, W1S 4JU

Telephone: +44 (0)20 7408 4080

 

Registrar

Equiniti

Aspect House, Spencer Road, Lancing, West Sussex, BN99 6DA

Telephone: 0371 384 2852*

Overseas: +44 (0)121 415 7047

 

Auditors and Tax Advisors

Grant Thornton UK LLP

101 Cambridge Science Park, Milton Road, Cambridge CB4 0FY

Telephone: +44 (0)1223 225600

 

Legal Advisors

Bristows LLP

100 Victoria Embankment, London, EC4Y 0PH

Telephone: +44 (0)20 7400 8000


Financial PR

FTI Consulting LLP

200 Aldersgate, Aldersgate Street, London, EC1A 4HD

Telephone: +44 (0)20 3727 1000

IXICO Plc Timeline

View All

Market Reports Including IXI

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.